Aravali Pharma and Lifesciences is a team of subject matter experts with more than three decades of experience in drug discovery and development. We provide end-to-end comprehensive solutions that equip our clients to innovate and succeed.
Pragya Bhateja, PhD
Founding Managing Director
Dr. Pragya is one of the founding members of Aravali Pharma and Lifesciences. Prior to initiation of Aravali, she held multiple senior strategic positions in global organizations such as Ranbaxy Research Laboratories and Daiichi Sankyo India Pharma Pvt Ltd. Dr. Pragya specializes in microbiology and anti-infective drug discovery. Over last two decades she executed and managed a portfolio from early target validation to late phase development. To her credit, she initiated, validated and successfully executed exclusive targets for therapeutic intervention. She has a practical approach, in identifying and strategizing unexplored opportunities in biomedical research in order to bring innovative medicines to the market. Her research focuses on screening of small molecules and developing assays for identification and validation of novel targets. Dr. Pragya has a Ph. D in microbiology from Jamia Millia Islamia University, New Delhi, India.
“She strongly believes that innovation is in everyone's DNA its just a matter of harnessing it in the right way through marrying human expertize and technology”.
Tridib Chaira, M Pharm
Founding Managing Director
Tridib has around two decades of academic and industrial experience in preclinical ADME and pharmacokinetics. He has worked with various multinational drug discovery companies like Zydus Cadila, Ranbaxy, Daiichi Sankyo to name a few.
Before Aravali Pharma and Lifescience, he was with Daiichi Sankyo and has lead a team of the researchers extensively involved in multiple therapeutic areas. He designed large number of PK/PD models across a wide range of disease areas providing strategic inputs to project teams to dial out ADME liability and early discovery formulation in PK, efficacy and toxicity studies. He is an expert in preclinical toxicity dose setting , finding margin of efficacy and various prediction models like compartmental modeling and simulations, human clinical dose estimation, clinical DDI risk assessment, prediction of urine PK profile and drug interaction models in animals.